HAIKOU, China, Dec. 28, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced the launch of N95 medical protective mask ("N95 mask").  

On December 26, Hainan Medical Products Administration issued the Registration Certificate of N95 medical protective masks to Hainan Helpson Medical & Biotechnology Co., Ltd., providing a strong material guarantee for further optimizing the industrial layout, production capacity and reserves of epidemic prevention materials in Hainan Province.

N95 Mask is a medical-level protection mask. It is used to filter particles, block droplets, blood, body fluids, secretions, etc. in the air under the medical work environment.

Recently, China has completely ended its strict quarantine and zero case policies in response to COVID-19 pandemic in the past three years. The number of COVID-19 infected people has exploded in all parts of China, and the demand of medical institutions and the public for high-level medical protective masks has increased significantly. The market is in short supply, and N95 masks at drugstores and other retailers are out of stock on a large scale.

Ms. Li Zhilin, CEO of China Pharma said: "Under the time the number of infected people has increased dramatically, and many of our colleagues have stuck to their posts under the epidemic situation. Thanks to our professional pharmaceutical production facilities, Hainan Medical Products Administration has treated our registration application as a special issue. Through providing us the green channel, they gave us advance technical guidance, to issue us the Registration Certificate at the fastest speed. Our fast reaction in expanding our product lines to N95 medical protective masks have demonstrated our firm commitment to providing excellent health products for the public."

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.